S&P 500   3,392.44 (+0.66%)
DOW   29,396.30 (+0.56%)
QQQ   237.38 (+1.13%)
AAPL   324.15 (+1.61%)
FB   218.14 (+0.16%)
MSFT   187.47 (+0.13%)
GOOGL   1,530.23 (+0.71%)
CGC   21.90 (-0.18%)
NVDA   312.87 (+5.50%)
BABA   222.97 (+1.11%)
MU   59.99 (+3.88%)
TSLA   920.23 (+7.20%)
AMD   58.93 (+3.59%)
ACB   1.71 (+4.28%)
F   8.01 (-0.62%)
NFLX   387.95 (+0.04%)
PRI   136.27 (+0.48%)
BAC   34.83 (+1.63%)
DIS   141.84 (+1.94%)
GILD   67.43 (+0.61%)
S&P 500   3,392.44 (+0.66%)
DOW   29,396.30 (+0.56%)
QQQ   237.38 (+1.13%)
AAPL   324.15 (+1.61%)
FB   218.14 (+0.16%)
MSFT   187.47 (+0.13%)
GOOGL   1,530.23 (+0.71%)
CGC   21.90 (-0.18%)
NVDA   312.87 (+5.50%)
BABA   222.97 (+1.11%)
MU   59.99 (+3.88%)
TSLA   920.23 (+7.20%)
AMD   58.93 (+3.59%)
ACB   1.71 (+4.28%)
F   8.01 (-0.62%)
NFLX   387.95 (+0.04%)
PRI   136.27 (+0.48%)
BAC   34.83 (+1.63%)
DIS   141.84 (+1.94%)
GILD   67.43 (+0.61%)
S&P 500   3,392.44 (+0.66%)
DOW   29,396.30 (+0.56%)
QQQ   237.38 (+1.13%)
AAPL   324.15 (+1.61%)
FB   218.14 (+0.16%)
MSFT   187.47 (+0.13%)
GOOGL   1,530.23 (+0.71%)
CGC   21.90 (-0.18%)
NVDA   312.87 (+5.50%)
BABA   222.97 (+1.11%)
MU   59.99 (+3.88%)
TSLA   920.23 (+7.20%)
AMD   58.93 (+3.59%)
ACB   1.71 (+4.28%)
F   8.01 (-0.62%)
NFLX   387.95 (+0.04%)
PRI   136.27 (+0.48%)
BAC   34.83 (+1.63%)
DIS   141.84 (+1.94%)
GILD   67.43 (+0.61%)
S&P 500   3,392.44 (+0.66%)
DOW   29,396.30 (+0.56%)
QQQ   237.38 (+1.13%)
AAPL   324.15 (+1.61%)
FB   218.14 (+0.16%)
MSFT   187.47 (+0.13%)
GOOGL   1,530.23 (+0.71%)
CGC   21.90 (-0.18%)
NVDA   312.87 (+5.50%)
BABA   222.97 (+1.11%)
MU   59.99 (+3.88%)
TSLA   920.23 (+7.20%)
AMD   58.93 (+3.59%)
ACB   1.71 (+4.28%)
F   8.01 (-0.62%)
NFLX   387.95 (+0.04%)
PRI   136.27 (+0.48%)
BAC   34.83 (+1.63%)
DIS   141.84 (+1.94%)
GILD   67.43 (+0.61%)
Log in

NASDAQ:CLRB - Cellectar Biosciences Stock Price, Forecast & News

$2.58
-0.59 (-18.61 %)
(As of 02/19/2020 02:55 PM ET)
Today's Range
$2.50
Now: $2.58
$3.16
50-Day Range
$2.25
MA: $2.61
$2.93
52-Week Range
$1.04
Now: $2.58
$3.75
Volume1.27 million shs
Average Volume150,152 shs
Market Capitalization$24.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Cellectar Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLRB
CUSIPN/A
Phone608-441-8120

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.26 per share

Profitability

Net Income$-13,240,000.00

Miscellaneous

Employees7
Market Cap$24.25 million
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.


Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work?

Cellectar Biosciences's stock reverse split on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences Inc (NASDAQ:CLRB) announced its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.04. View Cellectar Biosciences' Earnings History.

When is Cellectar Biosciences' next earnings date?

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Cellectar Biosciences.

What price target have analysts set for CLRB?

3 brokerages have issued 1-year target prices for Cellectar Biosciences' shares. Their forecasts range from $3.00 to $10.00. On average, they expect Cellectar Biosciences' share price to reach $6.33 in the next year. This suggests a possible upside of 145.5% from the stock's current price. View Analyst Price Targets for Cellectar Biosciences.

What is the consensus analysts' recommendation for Cellectar Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectar Biosciences.

Has Cellectar Biosciences been receiving favorable news coverage?

News coverage about CLRB stock has been trending very negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cellectar Biosciences earned a coverage optimism score of -3.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Cellectar Biosciences.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 311,900 shares, an increase of 88.9% from the January 15th total of 165,100 shares. Based on an average daily trading volume, of 123,600 shares, the days-to-cover ratio is presently 2.5 days. Currently, 3.4% of the shares of the company are sold short. View Cellectar Biosciences' Current Options Chain.

Who are some of Cellectar Biosciences' key competitors?

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy (BNP) and Hudbay Minerals (HBM).

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the folowing people:
  • Mr. James V. Caruso, Pres, CEO & Director (Age 60)
  • Mr. Jarrod Longcor, Chief Bus. Officer (Age 46)
  • Mr. Charles T. Bernhardt, Interim Chief Financial Officer (Age 58)
  • Gregory J. Lynch, Sec.

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.12%) and Game Plan Financial Advisors LLC (0.46%). Company insiders that own Cellectar Biosciences stock include James V Caruso, Jarrod Longcor and Stephen A Hill. View Institutional Ownership Trends for Cellectar Biosciences.

Which institutional investors are buying Cellectar Biosciences stock?

CLRB stock was bought by a variety of institutional investors in the last quarter, including Game Plan Financial Advisors LLC and Renaissance Technologies LLC. Company insiders that have bought Cellectar Biosciences stock in the last two years include James V Caruso and Jarrod Longcor. View Insider Buying and Selling for Cellectar Biosciences.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $2.58.

How big of a company is Cellectar Biosciences?

Cellectar Biosciences has a market capitalization of $24.25 million. The biopharmaceutical company earns $-13,240,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. Cellectar Biosciences employs 7 workers across the globe.View Additional Information About Cellectar Biosciences.

What is Cellectar Biosciences' official website?

The official website for Cellectar Biosciences is http://www.cellectar.com/.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]


MarketBeat Community Rating for Cellectar Biosciences (NASDAQ CLRB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe CLRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: What is a stock split?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel